Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...

Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...

Terumo Vietnam and Daiichi Sankyo Vietnam Co., Ltd. signed an MoU on February 26 to enhance cardiology expertise across ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...

Daiichi Sankyo announces establishment of upper limits for acquisition of own shares: Tokyo, Japan Saturday, March 1, 2025, 10:00 Hrs [IST] Daiichi Sankyo Company, Limited (hereaf ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

Terumo Vietnam Medical Equipment (Terumo Vietnam) and Daiichi Sankyo Vietnam have signed a Memorandum of Understanding (MoU) to collaborate on advancing cardiovascular expertise in Vietnam. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The global opioid analgesics market is poised for substantial growth, projected to expand from USD 43.3 billion in 2023 to USD 72.0 billion by 2033, at a robust Compound Annual Growth Rate (CAGR) of 5 ...